Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1984 1
1986 1
1990 1
1991 1
1993 1
1996 1
2000 1
2003 4
2004 2
2005 1
2006 2
2007 1
2008 2
2009 3
2010 2
2011 2
2012 4
2013 6
2014 5
2015 4
2016 3
2017 7
2018 6
2019 7
2020 9
2021 7
2022 4
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Esophageal Carcinoma"
Page 1
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, Shimizu C, Shimoi T, Kuboki Y, Matsubara N, Kitano A, Jikoh T, Lee C, Fujisaki Y, Ogitani Y, Yver A, Tamura K. Doi T, et al. Lancet Oncol. 2017 Nov;18(11):1512-1522. doi: 10.1016/S1470-2045(17)30604-6. Epub 2017 Oct 13. Lancet Oncol. 2017. PMID: 29037983 Clinical Trial.
We assessed its safety and tolerability in patients with advanced breast and gastric or gastro-oesophageal tumours. METHODS: This was an open-label, dose-escalation phase 1 trial done at two study sites in Japan. Eligible patients were at least 20 years old with breast or …
We assessed its safety and tolerability in patients with advanced breast and gastric or gastro-oesophageal tumours. METHODS: This was …
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT. Kang YK, et al. Lancet. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6. Lancet. 2017. PMID: 28993052 Clinical Trial.
BACKGROUND: Patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, two or more previous regimens of chemotherapy have a poor prognosis, and current guidelines do not recommend any specific treatments for these pa …
BACKGROUND: Patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, two or more …
Liver Cirrhosis and Portal Hypertension: How to Deal with Esophageal Varices?
Jothimani D, Rela M, Kamath PS. Jothimani D, et al. Med Clin North Am. 2023 May;107(3):491-504. doi: 10.1016/j.mcna.2023.01.002. Epub 2023 Feb 20. Med Clin North Am. 2023. PMID: 37001949 Review.
Clinically significant portal hypertension (CSPH) is an important prognostic milestone in patients with liver cirrhosis. This is a pre-symptomatic phase that predicts the development of varices, ascites and importantly increased risk of Hepatocellular carcinoma …
Clinically significant portal hypertension (CSPH) is an important prognostic milestone in patients with liver cirrhosis. This is a pr …
A good start of immunotherapy in esophageal cancer.
Zhao Q, Yu J, Meng X. Zhao Q, et al. Cancer Med. 2019 Aug;8(10):4519-4526. doi: 10.1002/cam4.2336. Epub 2019 Jun 23. Cancer Med. 2019. PMID: 31231980 Free PMC article. Review.
Considering the benefits of immunotherapy in advanced melanoma, non-small cell lung cancer, renal cell carcinoma, bladder cancers, and refractory Hodgkin lymphoma, we begin to consider whether immunotherapy is effective for esophageal cancer, which is extreme …
Considering the benefits of immunotherapy in advanced melanoma, non-small cell lung cancer, renal cell carcinoma, bladder cancers, an …
Risks and benefits of TIPS in HCC and other liver malignancies: a literature review.
Fichtl A, Seufferlein T, Zizer E. Fichtl A, et al. BMC Gastroenterol. 2023 Nov 20;23(1):403. doi: 10.1186/s12876-023-03047-0. BMC Gastroenterol. 2023. PMID: 37986043 Free PMC article. Review.
Its high efficacy and safety in the management of treatment-refractory ascites and variceal bleeding have been extensively proven. ...However, the role of liver malignancy in TIPS is debatable. Mostly, primary liver malignancies such as hepatocellular carcinoma (HCC …
Its high efficacy and safety in the management of treatment-refractory ascites and variceal bleeding have been extensively proven. .. …
Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival.
de Klerk LK, Patel AK, Derks S, Pectasides E, Augustin J, Uduman M, Raman N, Akarca FG, McCleary NJ, Cleary JM, Rubinson DA, Clark JW, Fitzpatrick B, Brais LK, Cavanaugh ME, Rode AJ, Jean MG, Lizotte PH, Nazzaro MJ, Severgnini M, Zheng H, Fuchs CS, Enzinger PC, Bass AJ. de Klerk LK, et al. J Immunother Cancer. 2021 Sep;9(9):e002472. doi: 10.1136/jitc-2021-002472. J Immunother Cancer. 2021. PMID: 34593617 Free PMC article. Clinical Trial.
METHODS: Pembrolizumab 200 mg every 3 weeks was tested in 49 patients with refractory esophageal cancer: 39 with adenocarcinoma and 10 with esophageal squamous cell carcinoma. ...CONCLUSIONS: Pembrolizumab monotherapy was modestly effective in refra …
METHODS: Pembrolizumab 200 mg every 3 weeks was tested in 49 patients with refractory esophageal cancer: 39 with adenocarcinom …
Current treatment options for esophageal diseases.
Martínek J, Akiyama JI, Vacková Z, Furnari M, Savarino E, Weijs TJ, Valitova E, van der Horst S, Ruurda JP, Goense L, Triadafilopoulos G. Martínek J, et al. Ann N Y Acad Sci. 2016 Oct;1381(1):139-151. doi: 10.1111/nyas.13146. Epub 2016 Jul 8. Ann N Y Acad Sci. 2016. PMID: 27391867 Review.
Exciting new developments-pharmacologic, endoscopic, and surgical-have arisen for the treatment of many esophageal diseases. Refractory gastroesophageal reflux disease presents a therapeutic challenge, and several new options have been proposed to overcome an insuff …
Exciting new developments-pharmacologic, endoscopic, and surgical-have arisen for the treatment of many esophageal diseases. Refra …
A risk prognostic model for patients with esophageal squamous cell carcinoma basing on cuproptosis and ferroptosis.
Li J, Liu J, Li J, Feng A, Nie Y, Yang Z, Zhang W. Li J, et al. J Cancer Res Clin Oncol. 2023 Oct;149(13):11647-11659. doi: 10.1007/s00432-023-05005-5. Epub 2023 Jul 5. J Cancer Res Clin Oncol. 2023. PMID: 37405477 Free PMC article.
However, whether the crossing of cuproptosis-related genes and ferroptosis-related genes can introduce some new idea, thus being used as a novel clinical and therapeutic predictor in esophageal squamous cell carcinoma (ESCC) remains unknown. ...RESULTS: Four …
However, whether the crossing of cuproptosis-related genes and ferroptosis-related genes can introduce some new idea, thus being used as a n …
Caustic ingestion in children-A review.
Arnold M, Numanoglu A. Arnold M, et al. Semin Pediatr Surg. 2017 Apr;26(2):95-104. doi: 10.1053/j.sempedsurg.2017.02.002. Epub 2017 Feb 3. Semin Pediatr Surg. 2017. PMID: 28550877 Review.
Serial dilation is the mainstay of oesophageal stricture therapy, with oesophageal replacement reserved for severe refractory strictures. Intra-lesional steroid or mitomycin C may decrease the dilatations required for severe strictures, although long-term eff …
Serial dilation is the mainstay of oesophageal stricture therapy, with oesophageal replacement reserved for severe refracto …
The portal hypertension syndrome: etiology, classification, relevance, and animal models.
Bosch J, Iwakiri Y. Bosch J, et al. Hepatol Int. 2018 Feb;12(Suppl 1):1-10. doi: 10.1007/s12072-017-9827-9. Epub 2017 Oct 24. Hepatol Int. 2018. PMID: 29064029 Review.
Two main disease stages are considered, compensated and decompensated cirrhosis, the first having good prognosis and being mostly asymptomatic, and the second being heralded by the appearance of bleeding or non-bleeding complications of portal hypertension. ...TIPS might b …
Two main disease stages are considered, compensated and decompensated cirrhosis, the first having good prognosis and being mostly asy …
85 results